A Novel Intranasal Immunotherapy to Reduce Neuroinflammation

Intranasal foralumab is successfully delivered to the cervical lymph nodes through a convenient nasal administration.

Here it binds to the surface of a CD4+ or a CD8+ T Cell

This stimulates the development of anti-inflammatory producing IL-10 T Regs

These T Regs migrate into the CNS where they infiltrate the blood brain barrier and produce IL-10 to promote a switch in the activated microglial state to a anti-inflammatory homeostatic state.

These IL-10 also suppress other cells of the CNS including astrocytes which reduces blood brain barrier degradation

These mechanisms help defend the CNS against chronic inflammatory damage.

Nasally administered foralumab is a promising therapeutic for numerous neuroinflammatory and neurodegenerative diseases.